- Polycystic ovarian syndrome (PCOS) treatments, encompassing various drug classes and surgical interventions, are increasingly vital for managing the complex symptoms and long-term health risks associated with this common hormonal disorder in women of reproductive age, due to their ability to address hormonal imbalances, metabolic dysfunction, and fertility issues
- The escalating demand for PCOS treatments is primarily fueled by the rising global prevalence of the condition, growing awareness among patients and healthcare providers, and advancements in diagnostic technologies and therapeutic approaches
- North America dominates the PCOS treatment market with a significant revenue share, estimated at approximately 45.1% in 2024, characterized by a high incidence rate of PCOS, advanced healthcare infrastructure, strong research and development activities by pharmaceutical companies, and high consumer awareness and healthcare expenditure. The U.S., in particular, accounts for a large portion of this share due to increased disposable income and focus on women's health
- Asia-Pacific is expected to be the fastest-growing region in the PCOS treatment market during the forecast period due to increasing urbanization, rising disposable incomes, and government initiatives to raise awareness about PCOS symptoms and diagnosis
- The Insulin-sensitizing agents segment is expected to dominate the PCOS treatment market. For instance, in 2024, insulin-sensitizing agents accounted for a share of 36.2% of the market, driven by the widespread recognition of insulin resistance as a key underlying factor in PCOS pathophysiology and their role in managing related metabolic issues like diabetes
